Home › Funds › BRAIDWELL LP › NBIX

BRAIDWELL LP position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

BRAIDWELL LP reported holding 336,171 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$56.7M, representing 2.23% of its reported portfolio and ranking #11 among its reported holdings. BRAIDWELL LP has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)336.17K sh
Reported value held$56.66M
Portfolio Weight2.23%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BRAIDWELL LP's NBIX position evolved

BRAIDWELL LP first disclosed a stake in NBIX in Q3 2023 at 968,024 shares (US$108.9M). The position peaked in Q2 2025 at 1,160,425 shares, worth US$145.9M. Across 12 filings, BRAIDWELL LP increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 336,171 shares valued at US$56.7M — a reduction of -315,950 shares quarter over quarter.. Notable position changes include a 26% trim in Q4 2023 (shares rose 5% over the following quarter), a 32% increase in Q1 2025 (shares rose 14% over the following quarter), a 48% trim in Q2 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 968.02K $108.90M New
Q4 2023 715.21K $94.24M Reduce
Q1 2024 730.21K $100.71M Add
Q2 2024 759.01K $104.49M Add
Q3 2024 917.67K $105.73M Add
Q4 2024 901.79K $123.09M Reduce
Q1 2025 1.19M $131.83M Add
Q2 2025 1.16M $145.85M Reduce
Q3 2025 880.28K $123.57M Reduce
Q4 2025 751.53K $106.59M Reduce
Q1 2026 652.12K $85.91M Reduce
Q2 2026 336.17K $56.66M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has BRAIDWELL LP held NBIX?

BRAIDWELL LP has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BRAIDWELL LP's current position in NBIX?

As of Q2 2026, BRAIDWELL LP holds 336.17K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $56.66M, representing 2.23% of its reported portfolio and ranking #11.

Has BRAIDWELL LP been buying or selling NBIX?

In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in NBIX. The position peaked in Q2 2025 at 1.16M shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.